Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes

P D Home, L Meneghini, U Wendisch, R E Ratner, T Johansen, T E Christensen, J Jendle, A P Roberts, K I Birkeland, P D Home, L Meneghini, U Wendisch, R E Ratner, T Johansen, T E Christensen, J Jendle, A P Roberts, K I Birkeland

Abstract

Aims: The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week, open-label, randomized trial. Health status, an important aspect of effective diabetes management, was also assessed.

Methods: Degludec (n = 59) or glargine (n = 59) were injected once daily, with insulin aspart at mealtimes. Health status assessment utilized the validated Short Form 36 Health Survey, version 2, which has two summary component scores for mental and physical well-being, each comprising four domains.

Results: At study end, HbA(1c) reductions were comparable between groups, but confirmed nocturnal hypoglycaemia was significantly less frequent with degludec [relative rate 0.42 (95% CI 0.25-0.69)], and overall hypoglycaemia numerically less frequent [relative rate 0.72 (95% CI 0.52-1.00)]. After 16 weeks, a significant improvement in Short Form 36 Health Survey mental component score of +3.01 (95% CI 0.32-5.70) was obtained for degludec against glargine, attributable to significant differences in the social functioning [+8.04 (95% CI 1.89-14.18)] and mental health domains [+2.46 (95% CI 0.10-4.82)]. For mental component score, Cohen's effect size was 0.42, indicating a small-to-medium clinically meaningful difference. The physical component score [+0.66 (95% CI -2.30 to 3.62)] and remaining domains were not significantly different between degludec and glargine.

Conclusions: In the context of comparable overall glycaemic control with glargine, degludec improved mental well-being as measured using the mental component score of the Short Form 36 Health Survey. The improvements in overall mental component score and the underlying social functioning and mental health domains with degludec compared with glargine may relate to the observed reduction in hypoglycaemic events.

© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Figures

FIGURE 1
FIGURE 1
The structure of the Short Form 36 Health Survey (SF-36) instrument. Elements of physical health are assessed in four domains, and elements of mental health in another four, and summarized in a physical and mental health component score. Each domain contains two to nine separate questions.

References

    1. Rubin RR, Peyrot M. Psychological issues and treatments for people with diabetes. J Clin Psychol. 2001;57:457–478.
    1. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;164:6–10.
    1. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4:S11–S18.
    1. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33:240–245.
    1. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543–2545.
    1. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523–1534.
    1. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab. 2008;10:S16–S24.
    1. Lundkvist J, Berne C, Bolinder B, Jönsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005;6:197–202.
    1. Jermendy G Hungarian RECAP Group. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. Health Qual Life Outcomes. 2008;6:88.
    1. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559.
    1. Jonassen I, Havelund S, Ribel U, Hoeg-Jensen T, Steensgaard DB, Johansen T, et al. Insulin degludec is a new generation ultra-long-acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes. 2010;59:A11.
    1. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia. 2010;53:S387.
    1. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34:661–665.
    1. Ware JE, Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User’s Manual for the SF-36v2(R) Health Survey. 2nd edn. Lincoln, RI: QualityMetric Incorporated; 2007.
    1. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–1912.
    1. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on diabetes management and work productivity. Value Health. 2011;14:665–671.
    1. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;91:363–370.

Source: PubMed

3
Iratkozz fel